Socinski, M., et al. (2004) Combined Modality Trials of the Cancer and Leukemia Group B in Stage III Non-Small-Cell Lung Cancer: Analysis of Factors Influencing Survival and Toxicity. Annals of Oncology, 15, 1033-1041.
https://doi.org/10.1093/annonc/mdh282

has been cited by the following article:

• TITLE: Molecular Targets of Curcumin and Future Therapeutic Role in Leukemia

  AUTHORS: Sabika Rafiq, Muhammad Hassan Raza, Mehwish Younas, Fariha Naeem, Romisha Adeeb, Javed Iqbal, Pervez Anwar, Umara Sajid, Hafiza Muniba Manzoor

  KEYWORDS: Curcumin, Antioxidant, Signaling Pathways, Apoptosis, Therapeutic Potential, Leukemic Load

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.6 No.4, April 23, 2018

  ABSTRACT: Leukemia is a most prevalent type of cancer around the globe. Due to major side effects of Chemotherapy and radiotherapy, scientists worked to explore the alternative source to treat leukemia. An alternative source for the treatment of leukemia existed in the form of curcumin, a natural phenolic compound extracted from curcuma longa plant. It exhibited anticancer properties reducing the tumor load via apoptosis and cell cycle arrested in various cancer cell lines and controlled tumor proliferation by blocking tumor inducing gene such as FLT3, Akt gene, ROS and NF-κB inhibition. At molecular level, curcumin plays a key therapeutic role in protection of normal cells by up regulation of NRF-2 that induces production of cellular antioxidants. It regulates various signaling pathways including NF-KB, JAK/STAT, PI3K/AKT and JNK pathways, thereby affecting cancer initiation, progression, and metastasis. This review described the potential of curcumin for treatment of leukemia; it affects different signaling cascades and their regulation. This study provides a preclinical foundation for future usage of curcumin in the treatment of cancer.